Contineum Therapeutics, Inc. Class A Common Stock

CTNMNASDAQHealthcare● Active

$11.44

$-0.05(-0.44%)

Market Cap$427700119

P/E Ratio—

52W High$16.33

52W Low$3.57

Avg Volume273K

Open$11.66

Beta0.89

Overview

Contineum Therapeutics, Inc. Class A Common Stock（CTNM）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

ctnm · 股价预测 · 3 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

Buy

3 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 3 · 买入占比: 66.7%

12 个月目标价

High

$16.00

Consensus

$16.00

+39.3% upside

Low

$16.00

Median: $16 · Last Close: $11.48

Contineum Therapeutics, Inc. Class A Common Stock（CTNM）的分析师共识为 Buy，基于过去 3 个月内 3 位华尔街分析师的评级。CTNM 的 12 个月平均目标价为 $16.00，相对当前价 $11.48 代表 +39.3% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$10.91	↓ 5.00%	$10.83	$10.99

1-day model range: $10.83–$10.99. Peak: $10.99 (-5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$6	$6	$6	-47.3%
2028	$4	$4	$5	-61.0%
2029	$4	$4	$4	-66.6%
2030	$3	$4	$4	-69.2%
2031	$3	—	$4	-70.6%

Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%

0Buy

1Neutral

13Sell

RSI (14)36.7Neutral

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · CTNM · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$12.04SELL

MA 10$12.72SELL

MA 20$13.19SELL

MA 50$13.21SELL

MA 100$13.61SELL

MA 200$12.43SELL

Current $CTNM · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$12.02SELL

EMA 10$12.50SELL

EMA 20$12.92SELL

EMA 50$13.20SELL

EMA 100$13.01SELL

EMA 200$12.25SELL

Current $CTNM · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2026-05-14	Morgan Stanley	Maintains	Equal Weight→Equal Weight
2026-03-06	Baird	Maintains	Outperform→Outperform
2026-01-08	Morgan Stanley	Downgrade ↓	Overweight→Equal Weight
2025-11-24	Baird	Maintains	Outperform→Outperform
2025-11-21	RBC Capital	Maintains	Outperform→Outperform
2025-08-18	Morgan Stanley	Maintains	Overweight→Overweight
2025-05-19	Morgan Stanley	Maintains	Overweight→Overweight
2025-05-15	RBC Capital	Maintains	Outperform→Outperform
2025-03-07	Baird	Maintains	Outperform→Outperform
2025-01-09	RBC Capital	Maintains	Outperform→Outperform

Morgan Stanley2026-05-14

Maintains

Equal Weight→Equal Weight

Baird2026-03-06

Maintains

Outperform→Outperform

Morgan Stanley2026-01-08

Downgrade ↓

Overweight→Equal Weight

Baird2025-11-24

Maintains

Outperform→Outperform

RBC Capital2025-11-21

Maintains

Outperform→Outperform

Morgan Stanley2025-08-18

Maintains

Overweight→Overweight

Morgan Stanley2025-05-19

Maintains

Overweight→Overweight

RBC Capital2025-05-15

Maintains

Outperform→Outperform

Baird2025-03-07

Maintains

Outperform→Outperform

RBC Capital2025-01-09

Maintains

Outperform→Outperform

Wall Street analysts have recently issued updated ratings on Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock. Of the recent 12 rating actions, 0 were upgrades and 1 were downgrades. 3 analysts currently cover CTNM.

分析师推荐趋势

Buy ratings2 → 0↓ 2

Hold ratings0 → 1↑ +1

Sell ratings0 → 0

CTNM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$7M

↑ 100.5% YoY

Revenue Next Year

$2M

↓ 68.0% YoY

EPS This Year

$-1.65

EPS Next Year

$-1.81

↑ 10.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CTNM EPS of $-1.65 for the current fiscal year, based on estimates from 5 analysts. The CTNM revenue forecast is $7M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

CTNM 股价预测由两类独立数据源支撑：来自 3 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CTNM 的共识目标价为 $16.00（+39.3% 上行空间），分析师共识为 Buy。

CTNM 的短期预测（明日）为 $10.91（-5.00%）。 CTNM 对 2027 年的股价预测均值为 $6。 CTNM 对 2030 年的预测区间为 $3–$4。

Contineum Therapeutics, Inc. Class A Common Stock 在 NASDAQ 上市，代码 CTNM。CTNM 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

CTNM 预测 · 8 个问题

根据 3 位华尔街分析师，CTNM 的 12 个月平均目标价为 $16.00，最高 $16.00、最低 $16.00。若有图表，中位目标价可在上方查看。相对当前价 $11.48，隐含约 +39.3% 的上行空间。

CTNM 目标价CTNM 分析师目标价CTNM 12个月目标价目标价 CTNM

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.